60 DEGREES PHARMACEUTICALS, INC. - 8-K Filing
If clinical trial results for tafenoquine in treating severe babesiosis support a New Drug Application (NDA) submission to the FDA by Q1 2028, 60 Degrees Pharmaceuticals intends to apply for a Commissioner’s National Priority Review Voucher. The company is disclosing this regulatory strategy as part of its development plans. (Items: 8.01 Other Events The Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim)
Tickers: $SXTP